Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, not yet approved by the MHRA or EMA for use in the UK
H.ParkS.LeeM
Approximately three-quarters of patients initiating oral Wegovy had not previously received a GLP-1 injection, according to NorstellaLinQ data When available quickly, claims and EMR data do what claims data alone cannot
Improved Skin Texture: With continued use, your skin will feel smoother, more hydrated, and healthier
It may signal the need for a dose adjustment, a dietary change, or an investigation into whether your medication has been stored properly, which brings us right back to color and appearance
If you have the time and feel strongly about this issue, contact your representatives and educate them before legislation appears